Summit Securities Group’s Teva Pharmaceuticals TEVA Stock Holding History

Summit Securities Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$312K	–	1361
2025 Q4	$312K	Buy	+10,000	New	+$246K	0.04%	255
2021 Q2	–	Sell	-216	Closed	-$249K	–	866
2021 Q1	$249K	Buy	+216	New	+$2.48K	0.03%	486
2019 Q3	–	Sell	-115	Closed	-$106K	–	406
2019 Q2	$106K	Buy	+115	New	+$1.39K	0.01%	311
2015 Q1	–	Sell	-345	Closed	-$90K	–	626
2014 Q4	$90K	Sell	345 -48	-12%	-$2.67K	0.03%	273
2014 Q3	$2K	Buy	+393	New	+$20.8K	﹤0.01%	618
2013 Q4	–	Sell	-335	Closed	-$3K	–	591
2013 Q3	$3K	Buy	335 +162	+94%	+$6.32K	﹤0.01%	328
2013 Q2	$2K	Buy	+173	New	+$6.74K	﹤0.01%	489

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Summit Securities Group's TEVA Position: Q2 2026 in Review

Summit Securities Group reduced its Teva Pharmaceuticals (TEVA) stake by 6.7% in Q2 2026, selling an estimated $16.7K and leaving 7,000 shares worth $237K. The position accounts for 0.02% of the portfolio, ranked #251.

Summit Securities Group first reported a position in TEVA in Q2 2013 and has held it in 16 quarters since. The position peaked at $2.09M in Q3 2014. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Summit Securities Group held 7,000 shares of Teva Pharmaceuticals worth $237K as of Q2 2026.
Summit Securities Group sold 500 Teva Pharmaceuticals shares in Q2 2026, an estimated $16.7K.
Teva Pharmaceuticals made up 0.02% of Summit Securities Group's portfolio in Q2 2026, its #251 holding.
Summit Securities Group first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
Summit Securities Group's Teva Pharmaceuticals position peaked at $2.09M in Q3 2014.
675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.